Aspira Women's Health Q2 revenue stable at $2.4M; H1 gross margin improves to 66.1%

Aspira Women's Health Inc.

2025-Q2 EPS reported -$0.16 revenue$222,000

Q2 product revenue $2.404M vs $2.423M YoY; commercial portfolio AUP up 12%.
H1 2025 revenue $4.683M (+2.3% YoY); gross margin 66.1% (vs 57.6% in H1 2024).
Operating expenses down 31% to $8.1M; cash burn reduced 41% to $4.8M in H1.
Sales force cut from 19 to 7 FTEs; sales per FTE up 156% in Q2.
CEO Mike Buhle reaffirms ENDOInform milestone completion by end of 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.